Lenabasum is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in clinical studies for systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.
Learn more Career Opportunities
Lenabasum is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in clinical studies for systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.
Learn more Career Opportunities
Lenabasum is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in clinical studies for systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.
Learn more Career Opportunities
Corbus Pharmaceuticals is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.
Our technology revolves around the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases.
Learn More
Corbus Pharmaceuticals is dedicated to developing therapeutics that help to better the lives of patients with rare chronic inflammatory conditions.
Learn MoreCorbus Pharmaceuticals is developing lenabasum for the treatment of rare, chronic and serious inflammatory and fibrotic diseases.
View Details| Preclinical | Phase 1 | Phase 2 | Phase 2b | Phase 3 | |
|---|---|---|---|---|---|
| Systemic Sclerosis |
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 2b Phase complete
|
Phase 3 Phase in progress
|
|
| Dermatomyositis |
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 2b Phase in progress
|
Phase 3 Phase not started
|
|
| Cystic Fibrosis |
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 2b Phase in progress
|
Phase 3 Phase not started
|
|
| Systemic Lupus Erythematosus |
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 2b Phase not started
|
Phase 3 Phase not started
|
A novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes.
